NASDAQ$INTS
Intensity Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
INTS reported Q3 2025 a net loss of $2.7M, diluted EPS of $-0.06.
For Q3 2025, INTS reported net loss was $2.7M, diluted EPS was $-0.06. The filing discusses operating performance, liquidity, and outlook in MD&A.
- Net loss $2.7M.
- Diluted EPS $-0.06.
- MD&A covers R&D, cash runway, and sector-specific risks.
Headline financials
Revenue & EPS history
Intensity Therapeutics · Revenue · Quarterly
$4M
Forward guidance
Outlook focuses on cash runway, pipeline milestones, and cost discipline as the company works toward profitability.
Tailwinds
- Cash and equivalents support operations into upcoming milestones.
- Clinical or product pipeline progress noted in MD&A.
Headwinds
- Ongoing operating losses and R&D spend pressure near-term earnings.
- Financing, dilution, or partnership timing may affect liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q3 2025
+0.8%
Avg return
Earnings day
-4.7%
Avg return
5 days after
+26.6%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+17.3%
Q4 2023
Best reaction
-6.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +4.4% | -6.7% | -26.9% | |
| Q3 2025 | -5.8% | -16.0% | -8.2% | |
| Q2 2025 | +7.2% | +15.1% | +11.9% | |
| Q1 2025 | -5.8% | -22.6% | -38.6% | |
| Q4 2024 | +0.5% | -18.3% | -18.7% | |
| Q3 2024 | -6.2% | -7.4% | -39.2% | |
| Q2 2024 | -4.2% | -11.1% | -17.1% | |
| Q1 2024 | +6.7% | +17.9% | +27.5% | |
| Q1 2023 | +6.7% | +17.9% | +27.5% | |
| Q4 2023 | +17.3% | +22.0% | +12.0% | |
| Q3 2023 | -4.0% | -22.8% | +263.2% | |
| Q3 2022 | -4.0% | -22.8% | +263.2% | |
| Q4 2022 | -0.4% | -5.1% | -19.0% | |
| Q2 2023 | -0.4% | -5.1% | -19.0% | |
| Q2 2022 | -0.4% | -5.1% | -19.0% | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro